EPI Health, LLC et al v. Taro Pharmaceuticals, Inc.
| Allergan, Inc., Aclaris Therapeutics, Inc. and EPI Health, LLC |
| Taro Pharmaceuticals, Inc. |
| 1:2019cv01910 |
| October 8, 2019 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on December 5, 2019. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 12 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent EPI Group, LLC for EPI Health, LLC filed by EPI Health, LLC. (Tigan, Jeremy) |
| Filing 11 FIRST AMENDED COMPLAINT FOR PATENT INFRINGEMENT against Taro Pharmaceuticals, Inc.- filed by EPI Health, LLC, Allergan, Inc.(fms) |
Filing 10
SO ORDERED, re #9 Stipulation filed by Allergan, Inc., Aclaris Therapeutics, Inc. EPI Health, LLC added. Aclaris Therapeutics, Inc. terminated. Signed by Judge Colm F. Connolly on 12/3/2019. (fms)
|
| Filing 9 STIPULATION and [Proposed] Order to Substitute Parties, Grant Leave to Amend Complaint, and Change Case Caption by Aclaris Therapeutics, Inc., Allergan, Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B)(Tigan, Jeremy) |
| Filing 8 STIPULATION TO EXTEND TIME for defendant Taro Pharmaceuticals, Inc. to answer, move, or otherwise respond to the Complaint to December 2, 2019 - - filed by Aclaris Therapeutics, Inc.. (Tigan, Jeremy) |
|
SO ORDERED, re #8 STIPULATION TO EXTEND TIME for defendant Taro Pharmaceuticals, Inc. to answer, move, or otherwise respond to the Complaint to December 2, 2019 - filed by Aclaris Therapeutics, Inc. Set/Reset Answer Deadlines: Taro Pharmaceuticals, Inc. answer due 12/2/2019. Signed by Judge Colm F. Connolly on 10/30/2019. (fms)
|
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) |
| Filing 7 AFFIDAVIT of Service for Summons, Complaint and Related Papers served on Taro Pharmaceuticals, Inc. on October 10, 2019, filed by Aclaris Therapeutics, Inc., Allergan, Inc.. (Tigan, Jeremy) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Allergan plc for Allergan, Inc. filed by Allergan, Inc.. (Oakes, Robert) |
| Summons Issued with Magistrate Consent Notice attached as to Taro Pharmaceuticals, Inc. on 10/9/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (amf) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed - filed by Aclaris Therapeutics, Inc. (amf) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,812,049 B2; 8,420,688 B2; 8,815,929 B2; 9,974,773 B2; and 10,335,391 B2. (amf) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/29/2019. Date of Expiration of Patent: SEE ATTACHED FORM.Thirty Month Stay Deadline: 3/1/2022. (amf) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (amf) |
| Filing 1 COMPLAINT FOR PATENT INFRINGEMENT - filed against Taro Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. (Filing fee $ 400, receipt number 0311-2750439) - filed by Allergan, Inc. and Aclaris Therapeutics, Inc. (Attachments: #1 Exhibits A-E, #2 Civil Cover Sheet)(amf) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
